• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by NextCure Inc.

    4/24/26 4:18:39 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NXTC alert in real time by email
    DEFA14A 1 tm261451d5_defa14a.htm DEFA14A

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 14A
    (Rule 14a-101)

     

    Proxy Statement Pursuant to Section 14(a)
    of the Securities Exchange Act of 1934

    Filed by the Registrant x

     

    Filed by a party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨Preliminary Proxy Statement
    ¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ¨Definitive Proxy Statement
    xDefinitive Additional Materials
    ¨Soliciting Material under §240.14a-12

     

    [MISSING IMAGE: lg_nextcure-4c.jpg]

     

    NextCure, Inc.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other Than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    xNo fee required.
    ¨Fee paid previously with preliminary materials.
    ¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

    GRAPHIC

    *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V95381-P51739 NEXTCURE, INC. 9000 VIRGINIA MANOR ROAD SUITE 200 BELTSVILLE, MD 20705 Your Vote Counts! NEXTCURE, INC. 2026 Annual Meeting to Be Held on June 18, 2026 Vote by June 17, 2026 11:59 PM ET You invested in NEXTCURE, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 18, 2026. Get informed before you vote View the Notice, Proxy Statement and Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 4, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Vote Virtually During the Meeting* June 18, 2026 11:00 AM ET Virtually at: www.virtualshareholdermeeting.com/NXTC2026

    Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V95382-P51739 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. 1. Election of two Class I Directors. Nominees: 1a. Anne Borgman, M.D. For 1b. John G. Houston, Ph.D. For 2. Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of NextCure, Inc. for the fiscal year ending December 31, 2026. For 3. Approval, on an advisory basis, of the compensation paid by Company to its named executive officers. For 4. Approval of an amendment and restatement of the Company’s 2019 Omnibus Incentive Plan to, among other items, increase the number of shares of common stock authorized for issuance thereunder. For NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting.

    Get the next $NXTC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NXTC

    DatePrice TargetRatingAnalyst
    11/7/2025$18.00Neutral → Buy
    Ladenburg Thalmann
    11/4/2022Buy → Neutral
    Ladenburg Thalmann
    3/1/2022$16.00Buy
    Ladenburg Thalmann
    11/5/2021$30.00 → $14.00Buy
    Needham
    More analyst ratings

    $NXTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sr VP, General Counsel Shaw Kevin G.

    4 - NextCure, Inc. (0001661059) (Issuer)

    2/3/26 4:07:22 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Sr VP, Dev. & Mfg. Kundu Sourav

    4 - NextCure, Inc. (0001661059) (Issuer)

    2/3/26 4:07:20 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by President & CEO Richman Michael

    4 - NextCure, Inc. (0001661059) (Issuer)

    2/3/26 4:07:18 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026

    BELTSVILLE, Md., April 21, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced a poster will be presented at ASCO 2026 highlighting Phase 1 data for SIM0505 in the treatment of solid tumors. ASCO 2026 is being held May 29 – June 2 in Chicago, Illinois. SIM0505 is an investigational antibody drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary

    4/21/26 10:15:00 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer

    The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SIM0505 for the treatment of women with platinum resistant ovarian cancer (PROC) Phase 1 data for SIM0505 to be presented at ASCO 2026; dose optimization in ovarian cancer expected to begin in Q2 2026 BELTSVILLE, Md., April 07, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced that the U.S. Food And Drug Administration (FDA) has granted Fast Track Designation for SIM0505 for the treatment of platinum-resistant ovarian cancer. SIM0505 is an

    4/7/26 8:05:00 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026

    BELTSVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company, today announced that an abstract for SIM0505 has been accepted for the American Society for Clinical Oncology (ASCO 2026) meeting being held May 29 – June 2 in Chicago, Illinois. SIM0505 is an investigational antibody drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor (TOPOi) payload. The ongoing open-label, Phase 1 s

    3/31/26 4:05:00 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NextCure upgraded by Ladenburg Thalmann with a new price target

    Ladenburg Thalmann upgraded NextCure from Neutral to Buy and set a new price target of $18.00

    11/7/25 8:06:56 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextCure downgraded by Ladenburg Thalmann

    Ladenburg Thalmann downgraded NextCure from Buy to Neutral

    11/4/22 1:03:13 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ladenburg Thalmann initiated coverage on NextCure with a new price target

    Ladenburg Thalmann initiated coverage of NextCure with a rating of Buy and set a new price target of $16.00

    3/1/22 7:18:07 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    SEC Filings

    View All

    SEC Form DEFA14A filed by NextCure Inc.

    DEFA14A - NextCure, Inc. (0001661059) (Filer)

    4/24/26 4:18:39 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by NextCure Inc.

    DEF 14A - NextCure, Inc. (0001661059) (Filer)

    4/24/26 4:15:23 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by NextCure Inc.

    10-K - NextCure, Inc. (0001661059) (Filer)

    3/5/26 4:26:11 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NextCure Inc.

    SC 13G/A - NextCure, Inc. (0001661059) (Subject)

    11/14/24 6:59:21 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by NextCure Inc.

    SC 13G/A - NextCure, Inc. (0001661059) (Subject)

    11/13/24 4:06:36 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by NextCure Inc.

    SC 13G - NextCure, Inc. (0001661059) (Subject)

    6/27/24 4:47:26 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    Leadership Updates

    Live Leadership Updates

    View All

    NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

    BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board. As an accomplished product developer whose expertise is focused on antibody-drug conjugates (ADCs), Dr. Dixit will support NextCure in its efforts to build and develop its proprietary ADCs, including LNCB74 directed to B7-H4. "We are delighted to have Dr. Dixit join our Scientific Advisory Board, where he will leverage his exceptional experience in developing antibody-drug c

    4/4/24 7:05:00 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board

    BELTSVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Lisa M. Coussens, PhD, FAACR, to its Scientific Advisory Board. As an accomplished translational tumor immunologist whose research is focused on the role immune cells play in tumor development, Dr. Coussens will support NextCure in its efforts to build and develop its proprietary pipeline of immunomedicines. "We are delighted to have Dr. Coussens join our Scientific Advisory Board, where she will leverage

    10/27/22 4:05:00 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

    BELTSVILLE, Md., March 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth quarter and full year 2020 financial results and provided a business update. “Our team has worked diligently throughout 2020 to advance our programs despite the difficult environment created by the COVID-19 pandemic. We are thrilled that Dr. Han Myint has recently joined NextCure as our Chief Medical Officer and we are poised to harness his expertise in oncology product development to further advance our product pipe

    3/4/21 4:05:00 PM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXTC
    Financials

    Live finance-specific insights

    View All

    NextCure to Host Virtual Oncology Pipeline Update Event on November 15, 2021

    BELTSVILLE, Md., Nov. 01, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company will host a Virtual Oncology Pipeline Update Event at 4:30 p.m. ET on Monday, November 15, 2021. During the event, NextCure will provide an update on its oncology pipeline, including data presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting. The event will also feature Roy Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Directo

    11/1/21 8:00:00 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care